001367.SZ
海森药业
SZSE · C 制造业 · CN
CNY 20.44
−6.24%Aug 20, 2026, 10:48 UTC
Hysen Pharmaceutical announced its 2026 first-half results with revenue of 251 million yuan, up 3.64% year-on-year, and net profit attributable to shareholders of 65.7354 million yuan, up 8.13%.
Source:Aug 20, 2026, 10:48 UTC
Hysen Pharmaceutical announced that former chairman Wang Shiyue resigned and Wang Yuxiao was elected as the new chairman; former CFO Pan Aijuan resigned and Wu Suzhen was appointed as the new CFO.
Source:Jul 12, 2026, 07:33 UTC
Hysen Pharmaceutical's shareholder Taiqi Investment prematurely terminated its planned share reduction plan after selling 120,100 shares.
Source: